🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “regorafenib” Clear

  1. IRINOTECAN, REGORAFENIB, Stivarga 40 mg film-coated tablets

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  2. MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  3. Regorafenib

    United Therapeutics Europe Ltd

    Gastro-Oesophageal Cancer

    phase 3 small molecule active

    1 trial

  4. Regorafenib (BAY73-4506)

    Bayer HealthCare AG

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  7. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  8. Regorafenib

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Gastroesophageal Junction

    phase 2 small molecule terminated

    1 trial

  9. Regorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Regorafenib

    phase 2 small molecule active

    1 trial

  10. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  11. DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    DC-CIK Treatment

    phase 1 other active

    1 trial

  12. Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

    Istituto Gentili S.r.l.

    MGMT-Methylated, IDH wild-type glioblastoma

    phase 1 other active

    1 trial

  13. Regorafenib and Sintilimab in combination with electroacupuncture

    The First People's Hospital of Lianyungang

    Colorectal Cancer Metastatic

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources